Rodin Therapeutics
Latest round
- Series C
Last raised
- Sep 2017
Total raised
- $40M
Investors
- 6
About Rodin Therapeutics
Based in Massachusetts, US, and founded in 2013, Rodin Therapeutics Inc. operates as a biopharmaceutical company that develops epigenetic drugs for neurological diseases. In November 2019, Alkermes acquired Rodin Therapeutics Inc. for USD 100 million upon completion and a further USD 850 million in milestone payments. The company’s focus lies on synaptopathies, a group of disorders characterized by impaired communication between nerve cells in the brain, such as Neurodegenerative, Neuropsychiatric, and Neurodevelopmental diseases. Their approach involves designing molecules that target specific protein complexes to activate genes crucial for learning and memory safely. This, in theory, could enhance synaptic integrity and improve neurological function. Rodin Therapeutics is particularly interested in diseases like Alzheimer's, Parkinson's, and schizophrenia, all of which involve synaptic dysfunction.
Who invested in Rodin Therapeutics
6 investors across 3 rounds
See all investors in Rodin Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Rodin Therapeutics
Who invested in Rodin Therapeutics?
Rodin Therapeutics has 6 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Rodin Therapeutics raised?
Rodin Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Rodin Therapeutics last raise money?
Rodin Therapeutics's most recent round on record is a Series C, in Sep 2017.
What does Rodin Therapeutics do?
Based in Massachusetts, US, and founded in 2013, Rodin Therapeutics Inc.
Where is Rodin Therapeutics headquartered?
Rodin Therapeutics is headquartered in Boston, US.
Which VCs invest in companies like Rodin Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Rodin Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Rodin Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.